BIOGEN INC (BIIB) Stock Fundamental Analysis
NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock
Overall BIIB gets a fundamental rating of 5 out of 10. We evaluated BIIB against 572 industry peers in the Biotechnology industry. BIIB scores excellent on profitability, but there are some minor concerns on its financial health. BIIB is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIIB was profitable.
BIIB had a positive operating cash flow in the past year.
BIIB had positive earnings in each of the past 5 years.
BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIIB has a better Return On Assets (5.70%) than 95.40% of its industry peers.
With an excellent Return On Equity value of 9.87%, BIIB belongs to the best of the industry, outperforming 95.22% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 9.36%, BIIB belongs to the top of the industry, outperforming 95.58% of the companies in the same industry.
BIIB had an Average Return On Invested Capital over the past 3 years of 12.12%. This is in line with the industry average of 13.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| ROIC | 9.36% |
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)12.12%
ROIC(5y)17.18%
1.3 Margins
BIIB has a better Profit Margin (16.81%) than 96.28% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
The Operating Margin of BIIB (25.92%) is better than 96.99% of its industry peers.
In the last couple of years the Operating Margin of BIIB has declined.
BIIB's Gross Margin of 75.59% is amongst the best of the industry. BIIB outperforms 85.31% of its industry peers.
In the last couple of years the Gross Margin of BIIB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.92% | ||
| PM (TTM) | 16.81% | ||
| GM | 75.59% |
OM growth 3Y-15.78%
OM growth 5Y-14.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.45%
GM growth 5Y-2.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BIIB is still creating some value.
Compared to 1 year ago, BIIB has more shares outstanding
BIIB has less shares outstanding than it did 5 years ago.
BIIB has a worse debt/assets ratio than last year.
2.2 Solvency
BIIB has an Altman-Z score of 2.66. This is not the best score and indicates that BIIB is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of BIIB (2.66) is better than 75.04% of its industry peers.
BIIB has a debt to FCF ratio of 3.56. This is a good value and a sign of high solvency as BIIB would need 3.56 years to pay back of all of its debts.
The Debt to FCF ratio of BIIB (3.56) is better than 94.34% of its industry peers.
BIIB has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
BIIB has a worse Debt to Equity ratio (0.28) than 70.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 3.56 | ||
| Altman-Z | 2.66 |
ROIC/WACC0.89
WACC10.55%
2.3 Liquidity
A Current Ratio of 1.26 indicates that BIIB should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.26, BIIB is doing worse than 84.25% of the companies in the same industry.
A Quick Ratio of 0.80 indicates that BIIB may have some problems paying its short term obligations.
BIIB has a Quick ratio of 0.80. This is amonst the worse of the industry: BIIB underperforms 90.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
BIIB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.16%.
Measured over the past years, BIIB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.49% on average per year.
BIIB shows a decrease in Revenue. In the last year, the revenue decreased by -3.86%.
BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.07% yearly.
EPS 1Y (TTM)3.16%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS Q2Q%-6.42%
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Sales Q2Q%-2.54%
3.2 Future
The Earnings Per Share is expected to grow by 6.24% on average over the next years.
The Revenue is expected to grow by 0.61% on average over the next years.
EPS Next Y10.84%
EPS Next 2Y6.36%
EPS Next 3Y6.36%
EPS Next 5Y6.24%
Revenue Next Year-2.91%
Revenue Next 2Y-2.05%
Revenue Next 3Y-0.67%
Revenue Next 5Y0.61%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.74 indicates a reasonable valuation of BIIB.
Based on the Price/Earnings ratio, BIIB is valued cheaply inside the industry as 97.70% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 28.19, BIIB is valued rather cheaply.
A Price/Forward Earnings ratio of 8.37 indicates a reasonable valuation of BIIB.
Based on the Price/Forward Earnings ratio, BIIB is valued cheaply inside the industry as 98.23% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.37, BIIB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.74 | ||
| Fwd PE | 8.37 |
4.2 Price Multiples
98.58% of the companies in the same industry are more expensive than BIIB, based on the Enterprise Value to EBITDA ratio.
98.23% of the companies in the same industry are more expensive than BIIB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.76 | ||
| EV/EBITDA | 8.06 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y6.36%
EPS Next 3Y6.36%
5. Dividend
5.1 Amount
No dividends for BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOGEN INC
NASDAQ:BIIB (1/22/2025, 8:07:25 PM)
After market: 142.75 0 (0%)142.75
+1.77 (+1.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.13%
Inst Owner Change-0.12%
Ins Owners0.13%
Ins Owner Change-3.32%
Market Cap20.80B
Analysts75.24
Price Target243.18 (70.35%)
Short Float %2.54%
Short Ratio2.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.05%
Min EPS beat(2)5.5%
Max EPS beat(2)28.61%
EPS beat(4)4
Avg EPS beat(4)10.01%
Min EPS beat(4)1.62%
Max EPS beat(4)28.61%
EPS beat(8)8
Avg EPS beat(8)8.49%
EPS beat(12)10
Avg EPS beat(12)8.67%
EPS beat(16)13
Avg EPS beat(16)8.57%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)1.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-5.08%
Max Revenue beat(4)1.48%
Revenue beat(8)5
Avg Revenue beat(8)0.42%
Revenue beat(12)7
Avg Revenue beat(12)0.61%
Revenue beat(16)9
Avg Revenue beat(16)0.82%
PT rev (1m)-4.42%
PT rev (3m)-11.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.65%
EPS NY rev (1m)0%
EPS NY rev (3m)1.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.74 | ||
| Fwd PE | 8.37 | ||
| P/S | 2.17 | ||
| P/FCF | 11.76 | ||
| P/OCF | 9.78 | ||
| P/B | 1.27 | ||
| P/tB | 307.72 | ||
| EV/EBITDA | 8.06 |
EPS(TTM)16.33
EY11.44%
EPS(NY)17.06
Fwd EY11.95%
FCF(TTM)12.14
FCFY8.5%
OCF(TTM)14.6
OCFY10.23%
SpS65.93
BVpS112.26
TBVpS0.46
PEG (NY)0.81
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| ROCE | 10.88% | ||
| ROIC | 9.36% | ||
| ROICexc | 10.11% | ||
| ROICexgc | 43.72% | ||
| OM | 25.92% | ||
| PM (TTM) | 16.81% | ||
| GM | 75.59% | ||
| FCFM | 18.41% |
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)12.12%
ROIC(5y)17.18%
ROICexc(3y)14.77%
ROICexc(5y)20.81%
ROICexgc(3y)31.37%
ROICexgc(5y)43%
ROCE(3y)14.1%
ROCE(5y)19.98%
ROICexcg growth 3Y-19.11%
ROICexcg growth 5Y-16.33%
ROICexc growth 3Y-29.06%
ROICexc growth 5Y-22.85%
OM growth 3Y-15.78%
OM growth 5Y-14.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.45%
GM growth 5Y-2.68%
F-Score6
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 3.56 | ||
| Debt/EBITDA | 1.46 | ||
| Cap/Depr | 57% | ||
| Cap/Sales | 3.73% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 68.18% | ||
| Profit Quality | 109.49% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | 2.66 |
F-Score6
WACC10.55%
ROIC/WACC0.89
Cap/Depr(3y)56.77%
Cap/Depr(5y)77.88%
Cap/Sales(3y)2.75%
Cap/Sales(5y)3.4%
Profit Quality(3y)119.62%
Profit Quality(5y)111.92%
High Growth Momentum
Growth
EPS 1Y (TTM)3.16%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS Q2Q%-6.42%
EPS Next Y10.84%
EPS Next 2Y6.36%
EPS Next 3Y6.36%
EPS Next 5Y6.24%
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Sales Q2Q%-2.54%
Revenue Next Year-2.91%
Revenue Next 2Y-2.05%
Revenue Next 3Y-0.67%
Revenue Next 5Y0.61%
EBIT growth 1Y3.07%
EBIT growth 3Y-24.11%
EBIT growth 5Y-19.83%
EBIT Next Year37.69%
EBIT Next 3Y12.79%
EBIT Next 5Y11.67%
FCF growth 1Y-18.63%
FCF growth 3Y-30.48%
FCF growth 5Y-25.27%
OCF growth 1Y-11.28%
OCF growth 3Y-28.48%
OCF growth 5Y-24.21%